The preclinical stages of T1D generally occur over a period of years and are characterized by the presence of islet autoantibodies in peripheral blood that target insulin and pancreatic β cell proteins, the subsequent development of impaired glucose tolerance, and then clinical T1D onset marked by hyperglycemia and the need for lifelong insulin treatment (7). This evidence concerns the gene INS and type 1 diabetes mellitus.